CY1120742T1 - Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων - Google Patents

Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων

Info

Publication number
CY1120742T1
CY1120742T1 CY181101037T CY181101037T CY1120742T1 CY 1120742 T1 CY1120742 T1 CY 1120742T1 CY 181101037 T CY181101037 T CY 181101037T CY 181101037 T CY181101037 T CY 181101037T CY 1120742 T1 CY1120742 T1 CY 1120742T1
Authority
CY
Cyprus
Prior art keywords
lxr
disorders
treatment
conditions
skin diseases
Prior art date
Application number
CY181101037T
Other languages
English (en)
Inventor
Raju Mohan
Original Assignee
Ralexar Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ralexar Therapeutics Inc filed Critical Ralexar Therapeutics Inc
Publication of CY1120742T1 publication Critical patent/CY1120742T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Περιγραφόμενοι στο παρόν είναι ρυθμιστές Χ υποδοχέα ήπατος (LXR) και μέθοδοι χρήσης ρυθμιστών LXR στη θεραπεία δερματικών ασθενειών, διαταραχών ή καταστάσεων. Επίσης περιγραφόμενες στο παρόν είναι φαρμακευτικές συνθέσεις που περιέχουν τέτοιες ενώσεις.
CY181101037T 2012-03-02 2018-10-08 Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων CY1120742T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606160P 2012-03-02 2012-03-02
PCT/US2013/028438 WO2013130892A1 (en) 2012-03-02 2013-02-28 Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions

Publications (1)

Publication Number Publication Date
CY1120742T1 true CY1120742T1 (el) 2019-12-11

Family

ID=49083313

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181101037T CY1120742T1 (el) 2012-03-02 2018-10-08 Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων

Country Status (25)

Country Link
US (5) US8987318B2 (el)
EP (2) EP2820013B9 (el)
JP (2) JP6378630B2 (el)
KR (1) KR102112879B1 (el)
CN (1) CN104284893B (el)
AU (1) AU2013225840B2 (el)
BR (1) BR112014021515A2 (el)
CA (1) CA2866113C (el)
CY (1) CY1120742T1 (el)
DK (1) DK2820013T3 (el)
ES (1) ES2691079T3 (el)
HK (1) HK1206030A1 (el)
HR (1) HRP20181623T1 (el)
HU (1) HUE040231T2 (el)
IL (1) IL234413B (el)
LT (1) LT2820013T (el)
MX (1) MX361349B (el)
NZ (1) NZ629636A (el)
PL (1) PL2820013T3 (el)
PT (1) PT2820013T (el)
RS (1) RS57863B9 (el)
SG (2) SG11201405378VA (el)
SI (1) SI2820013T1 (el)
TR (1) TR201815013T4 (el)
WO (1) WO2013130892A1 (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040231T2 (hu) 2012-03-02 2019-02-28 Ralexar Therapeutics Inc Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére
JP6456909B2 (ja) * 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
CN104151300B (zh) * 2013-05-15 2018-07-13 中国医学科学院医药生物技术研究所 一组2,3-二取代的苯并喹唑啉类的肝x受体的激动剂及用途
CA2923178A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
ES2804304T3 (es) 2013-09-04 2021-02-05 Ellora Therapeutics Inc Moduladores del receptor X hepático (LXR)
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
US20190365784A1 (en) 2015-12-30 2019-12-05 Raúl Enrique MASSONE Use of brassinosteroid analogs for the treatment of dermal disorders by selectively modulating liver x receptors (lxr) and dermal disease treatment by brassinosteroid analogs acting as selective liver x receptor (lxr) modulators
EP3402477A4 (en) 2016-01-11 2019-08-21 The Rockefeller University METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
EP3999055A1 (en) 2019-07-15 2022-05-25 Novartis AG Methods for treating meibomian gland dysfunction with liver x receptor agonists
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
WO2022249006A1 (en) * 2021-05-24 2022-12-01 Novartis Ag Use of 1,2,4-oxadiazole derivatives as liver x receptor agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1199771A (en) * 1915-07-01 1916-10-03 Bates Valve Bag Co Wire-twisting machine.
JP2004509161A (ja) 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2486651A1 (en) 2002-05-24 2003-12-04 Pharmacia Corporation Sulfone liver x-receptor modulators
MXPA04011691A (es) 2002-05-24 2005-09-12 Pharmacia Corp Moduladores del receptor x anilino hepaticos.
EP1572660B1 (en) 2002-12-20 2011-01-26 X-Ceptor Therapeutics, Inc. Isoquinolinone derivatives and their use as therapeutic agents
JP2006193426A (ja) 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
WO2005113499A1 (ja) 2004-05-20 2005-12-01 Sankyo Company, Limited インドール化合物
TW200606133A (en) 2004-06-30 2006-02-16 Sankyo Co Substituted benzene compounds
MX2007000791A (es) 2004-08-03 2007-03-23 Wyeth Corp Indazoles utiles en el tratamiento de enfermedades cardiovasculares.
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
US7213797B2 (en) 2005-05-20 2007-05-08 Garland Jerome Gaskins Deck board straightener
CA2613522A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
CN101248049B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 咪唑类lxr调节剂
US8008303B2 (en) 2005-09-16 2011-08-30 Astrazeneca Ab Biphenyl derivatives and their use in treating hepatitis C
WO2007034279A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
EP1948636A2 (en) 2005-11-14 2008-07-30 Irm Llc Compounds and compositions as lxr modulators
EP1849781A1 (en) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments
TW200825054A (en) 2006-10-18 2008-06-16 Wyeth Corp Quinoline compounds
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
WO2008104077A1 (en) * 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
MX2009012474A (es) 2007-05-18 2009-12-18 Wyeth Corp Compuestos de quinazolina.
US20090069288A1 (en) * 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
KR101171507B1 (ko) 2007-08-13 2012-08-07 에프. 호프만-라 로슈 아게 신규 피페라진 아마이드 유도체
EP2231617A1 (en) 2007-12-21 2010-09-29 Wyeth LLC Benzimidazole compounds
EP2231660A1 (en) 2007-12-21 2010-09-29 Wyeth LLC Imidazo [1,2-a] pyridine compounds
CA2724232A1 (en) * 2008-05-13 2009-11-19 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
US8063088B2 (en) 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
EP2352725A1 (en) 2008-11-07 2011-08-10 Wyeth LLC Quinoxaline-based lxr modulators
WO2010059627A1 (en) 2008-11-19 2010-05-27 Wyeth Llc Polar quinazolines as liver x receptors ( lxrs ) modulators
JP2012513399A (ja) 2008-12-22 2012-06-14 シェーリング コーポレイション γ−セクレターゼ調節剤
US20120058133A1 (en) * 2009-02-19 2012-03-08 President And Fellows Of Harvard College Inhibition of trna synthetases and therapeutic applications thereof
CA2753313A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
ES2620451T3 (es) 2009-05-28 2017-06-28 Exelixis Patent Company Llc Moduladores de los LXR
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
GB0919757D0 (en) 2009-11-12 2009-12-30 Johnson Matthey Plc Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
JPWO2012020820A1 (ja) * 2010-08-11 2013-10-28 大正製薬株式会社 ヘテロアリール−ピラゾール誘導体
CN103180316A (zh) * 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
AR088728A1 (es) 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
HUE040231T2 (hu) 2012-03-02 2019-02-28 Ralexar Therapeutics Inc Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére
JP6320382B2 (ja) 2012-08-13 2018-05-09 ザ ロックフェラー ユニヴァーシティ メラノーマの処置および診断
CA2923178A1 (en) 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
ES2804304T3 (es) 2013-09-04 2021-02-05 Ellora Therapeutics Inc Moduladores del receptor X hepático (LXR)

Also Published As

Publication number Publication date
WO2013130892A1 (en) 2013-09-06
RS57863B1 (sr) 2018-12-31
JP6800922B2 (ja) 2020-12-16
AU2013225840A1 (en) 2014-09-18
AU2013225840B2 (en) 2017-11-23
IL234413B (en) 2018-05-31
US8987318B2 (en) 2015-03-24
NZ629636A (en) 2017-02-24
TR201815013T4 (tr) 2018-11-21
JP2015512883A (ja) 2015-04-30
US20150045399A1 (en) 2015-02-12
CN104284893B (zh) 2017-04-19
EP3441390A1 (en) 2019-02-13
MX2014010537A (es) 2015-03-09
EP2820013B1 (en) 2018-07-11
JP2018184467A (ja) 2018-11-22
US20150152094A1 (en) 2015-06-04
JP6378630B2 (ja) 2018-08-22
US20210101895A1 (en) 2021-04-08
ES2691079T9 (es) 2019-02-08
PL2820013T3 (pl) 2019-01-31
KR102112879B1 (ko) 2020-05-19
US20180370959A1 (en) 2018-12-27
BR112014021515A2 (pt) 2018-03-13
EP2820013A1 (en) 2015-01-07
ES2691079T3 (es) 2018-11-23
RS57863B9 (sr) 2019-10-31
HUE040231T2 (hu) 2019-02-28
CA2866113A1 (en) 2013-09-06
EP2820013A4 (en) 2015-11-11
KR20140146089A (ko) 2014-12-24
HRP20181623T1 (hr) 2018-12-14
LT2820013T (lt) 2018-10-25
MX361349B (es) 2018-12-04
SG11201405378VA (en) 2014-09-26
DK2820013T3 (en) 2018-10-29
SI2820013T1 (sl) 2018-11-30
CA2866113C (en) 2020-05-12
EP2820013B9 (en) 2019-01-09
SG10201607345YA (en) 2016-11-29
PT2820013T (pt) 2018-10-25
US20170334897A1 (en) 2017-11-23
US9637481B2 (en) 2017-05-02
HK1206030A1 (en) 2015-12-31
CN104284893A (zh) 2015-01-14

Similar Documents

Publication Publication Date Title
CY1120742T1 (el) Ρυθμιστες του υποδοχεα χ ηπατος (lxr) για τη θεραπεια δερματικων ασθενειων, διαταραχων και καταστασεων
CY1124055T1 (el) Ετεροκυκλικες ενωσεις ως ανοσοδιαμορφωτες
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1121989T1 (el) Φαρμακοτεχνικες μορφες αντισωματων
CY1124918T1 (el) Ρυθμιστες ccr2
CY1124595T1 (el) Ρυθμιση δραστικοτητας συμπληρωματος
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
CY1124059T1 (el) Αζαβενζιμιδαζολια και χρηση αυτων ως ρυθμιστες υποδοχεα ampa
UY35427A (es) Compuestos y sus usos en la modulación de la hemoglobina
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
GT201500069A (es) Piridinonas bicìclicas novedosas
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
CY1123216T1 (el) Αναστολεις της gls1 για την αντιμετωπιση νοσων
CY1121326T1 (el) Υποκατεστημενη 2,4 διαμινο-κινολινη ως νεοι αντικαρκινικοι παραγοντες
DOP2015000170A (es) Compuestos químicos